Psilocybe mushrooms, psilocybin & psilocin



Jump to:


Page 6 (2017-2018)



Page 6

Bogenschutz & Forcehimes (2017). Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. Journal of Humanistic Psychology.

Brown et al. (2017). Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clinical Pharmacokinetics.

Carhart-Harris et al. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports.

de Veen et al. (2017). Psilocybin for treating substance use disorders? Expert Review of Neurotherapeutics.

Dinis-Oliveira (2017). Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metabolism Reviews.

Fricke, Blei & Hoffmeister (2017). Enzymatic synthesis of psilocybin. Angewandte Chemie International Edition.

Geller (2017). Can Psilocybin Treat Severe Depression? NEJM Journal Watch. Psychiatry.

Johnson & Griffiths (2017). Potential therapeutic effects of psilocybin. Neurotherapeutics.

Johnson et al. (2017). An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology.

Johnson, Garcia-Romeu & Griffiths (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse.

Johnson et al. (2017). "Long-term follow-up of psilocybin-facilitated smoking cessation": Corrigendum. The American Journal of Drug and Alcohol Abuse.

Lewis et al. (2017). Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. NeuroImage.

Mahapatra & Gupta (2017). Role of psilocybin in the treatment of depression. Therapeutic Advances in Psychopharmacology.

Pokorny et al. (2017). Effect of psilocybin on empathy and moral decision-making. International Journal of Neuropsychopharmacology.

Roseman et al. (2017). Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology.

Schartner et al. (2017). Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Scientific Reports.

Sellers (2017). Psilocybin: Good Trip or Bad Trip. Clinical Pharmacology and Therapeutics.

Strauss (2017). Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia. The Medical Journal of Australia.

Swift et al. (2017). Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress. The Journal of Humanistic Psychology.

Thomas, Malcolm & Lastra (2017). Psilocybin-assisted therapy: A review of a novel treatment for psychiatric disorders. Journal of Psychoactive Drugs.

Barnby & Mehta. (2018). Psilocybin and Mental Health-Don't Lose Control. Frontiers in Psychiatry.

Blei et al. (2018). Biocatalytic production of psilocybin and derivatives in tryptophan synthase-enhanced reactions. Chemistry.

Bogenschutz et al. (2018). Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Frontiers in Pharmacology.

Bravermanová et al. (2018). Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—Study on P300 and mismatch negativity in healthy volunteers. Psychopharmacology.

Carbonaro et al. (2018). Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Similarities and differences in subjective experiences. Psychopharmacology.

Carhart-Harris et al. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology.

Carrillo et al. (2018). Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. Journal of Affective Disorders.

Daniel & Haberman (2018). Clinical potential of psilocybin as a treatment for mental health conditions. The Mental Health Clinician.

Fricke et al. (2018). Production options for psilocybin - the making of the magic. Chemistry.

Erritzoe et al. (2018). Effects of psilocybin therapy on personality structure. Acta Psychiatrica Scandinavica.

Gabay et al. (2018). Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. Science Reports.

Geiger, Wurst & Daniels. (2018). DARK Classics in Chemical Neuroscience: Psilocybin. ACS Chemical Neuroscience.

Griffiths et al. (2018). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology.

Grimm et al. (2018). Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. European Neuropsychopharmacology.

Hendricks et al. (2018). The relationships of classic psychedelic use with criminal behavior in the United States adult population. Journal of Psychopharmacology.

Johnson et al. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology.

Lyons & Carhart-Harris (2018). Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. Journal of Psychopharmacology.

Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Frontiers in Pharmacology.

Nicholas et al. (2018). High dose psilocybin is associated with positive subjective effects in healthy volunteers. Journal of Psychopharmacology.

Noorani et al. (2018). Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology.

Ramachandran et al. (2018). Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). Neurocase.

Roseman, Nutt & Carhart-Harris (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology.

Schenberg (2018) Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology.

Stroud et al. (2018). Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology.

Whelan & Johnson (2018). Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? Pain Management.